13586 Federal Register / Vol. 86, No. 44 / Tuesday, March 9, 2021 / Notices 

calendarpad/calendar.html. Interested 

parties should check the Commission’s 

website periodically for updates. 

Requests to appear at the hearing should 

be filed in writing with the Secretary to 

the Commission on or before May 6, 

2021. A nonparty who has testimony 

that may aid the Commission’s 

deliberations may request permission to 

present a short statement at the hearing. 

All parties and nonparties desiring to 

appear at the hearing and make oral 

presentations should attend a 

prehearing conference to be held at 9:30 

a.m. on May 7, 2021, if deemed 

necessary. Oral testimony and written 

materials to be submitted at the public 

hearing are governed by sections 

201.6(b)(2), 201.13(f), and 207.24 of the 

Commission’s rules. Parties must submit 

any request to present a portion of their 

hearing testimony in camera no later 

than 7 business days prior to the date of 

the hearing. 

Written submissions.—Each party 

who is an interested party shall submit 

a prehearing brief to the Commission. 

Prehearing briefs must conform with the 

provisions of § 207.23 of the 

Commission’s rules; the deadline for 

filing is May 4, 2021. Parties may also 

file written testimony in connection 

with their presentation at the hearing, as 

provided in § 207.24 of the 

Commission’s rules, and posthearing 

briefs, which must conform with the 

provisions of section 207.25 of the 

Commission’s rules. The deadline for 

filing posthearing briefs is May 17, 

2021. In addition, any person who has 

not entered an appearance as a party to 

the investigations may submit a written 

statement of information pertinent to 

the subject of the investigations, 

including statements of support or 

opposition to the petition, on or before 

May 17, 2021. On June 4, 2021, the 

Commission will make available to 

parties all information on which they 

have not had an opportunity to 

comment. Parties may submit final 

comments on this information on or 

before June 8, 2021, but such final 

comments must not contain new factual 

information and must otherwise comply 

with § 207.30 of the Commission’s rules. 

All written submissions must conform 

with the provisions of § 201.8 of the 

Commission’s rules; any submissions 

that contain BPI must also conform with 

the requirements of §§ 201.6, 207.3, and 

207.7 of the Commission’s rules. The 

Commission’s Handbook on Filing 

Procedures, available on the 

Commission’s website at https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf, elaborates 

upon the Commission’s procedures with 

respect to filings. 

Additional written submissions to the 

Commission, including requests 

pursuant to § 201.12 of the 

Commission’s rules, shall not be 

accepted unless good cause is shown for 

accepting such submissions, or unless 

the submission is pursuant to a specific 

request by a Commissioner or 

Commission staff. 

In accordance with §§ 201.16(c) and 

207.3 of the Commission’s rules, each 

document filed by a party to the 

investigations must be served on all 

other parties to the investigations (as 

identified by either the public or BPI 

service list), and a certificate of service 

must be timely filed. The Secretary will 

not accept a document for filing without 

a certificate of service. 

Authority: These investigations are being 

conducted under authority of title VII of the 

Tariff Act of 1930; this notice is published 

pursuant to § 207.21 of the Commission’s 

rules. 

By order of the Commission. 

Issued: March 4, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–04860 Filed 3–8–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–802] 

Bulk Manufacturer of Controlled 

Substances Application: Patheon 

Pharmaceuticals Inc 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Patheon Pharmaceuticals Inc 

has applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before May 10, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 10, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on February 2, 2021, 

Patheon Pharmaceuticals Inc, 2110 East 

Galbraith Road, Cincinnati, Ohio 

45237–1625, applied to be registered as 

a bulk manufacturer of the following 

basic class of controlled substance: 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

The company plans to manufacture 

the above-listed controlled substance as 

Active Pharmaceutical Ingredient (API) 

that will be further synthesized into 

Food and Drug Administrationapproved dosage forms. No other 

activities for this drug code are 

authorized for this registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–04809 Filed 3–8–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–804] 

Bulk Manufacturer of Controlled 

Substances Application: Stepan 

Company 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Stepan Company has applied 

to be registered as a bulk manufacturer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before May 10, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 10, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on February 8, 2021, 

Stepan Company, 100 West Hunter 

Avenue, Maywood, New Jersey 07607– 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 44 / Tuesday, March 9, 2021 / Notices 13587 

1021, applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Cocaine ........................... 9041 II 

Ecgonine .......................... 9180 II 

The company plans to manufacture 

the above-listed controlled substances 

in bulk for distribution to its customers. 

No other activity for these drug codes is 

authorized for this registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–04808 Filed 3–8–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–803] 

Bulk Manufacturer of Controlled 

Substances Application: Bulk 

Manufacturer of Marihuana: Groff NA 

Hemplex LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: The Drug Enforcement 

Administration (DEA) is providing 

notice of an application it has received 

from an entity applying to be registered 

to manufacture in bulk basic class(es) of 

controlled substances listed in schedule 

I. DEA intends to evaluate this and other 

pending applications according to its 

regulations governing the program of 

growing marihuana for scientific and 

medical research under DEA 

registration. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefor, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before May 10, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW 8701 

Morrissette Drive, Springfield, Virginia 

22152. To ensure proper handling of 

comments, please reference Docket No. 

DEA–803 in all correspondence, 

including attachments. 

SUPPLEMENTARY INFORMATION: The 

Controlled Substances Act (CSA) 

prohibits the cultivation and 

distribution of marihuana except by 

persons who are registered under the 

CSA to do so for lawful purposes. In 

accordance with the purposes specified 

in 21 CFR 1301.33(a), DEA is providing 

notice that the entity identified below 

has applied for registration as a bulk 

manufacturer of schedule I controlled 

substances. In response, registered bulk 

manufacturers of the affected basic 

class(es), and applicants therefor, may 

file written comments on or objections 

of the requested registration, as 

provided in this notice. This notice does 

not constitute any evaluation or 

determination of the merits of the 

application submitted. 

The applicant plans to manufacture 

bulk active pharmaceutical ingredients 

(APIs) for product development and 

distribution to DEA-registered 

researchers. If the application for 

registration is granted, the registrant 

would not be authorized to conduct 

other activity under this registration 

aside from those coincident activities 

specifically authorized by DEA 

regulations. DEA will evaluate the 

application for registration as a bulk 

manufacturer for compliance with all 

applicable laws, treaties, and 

regulations and to ensure adequate 

safeguards against diversion are in 

place. 

As this applicant has applied to 

become registered as a bulk 

manufacturer of marihuana, the 

application will be evaluated under the 

criteria of 21 U.S.C. 823(a). DEA will 

conduct this evaluation in the manner 

described in the rule published at 85 FR 

82333 on December 18, 2020, and 

reflected in DEA regulations at 21 CFR 

part 1318. 

In accordance with 21 CFR 

1301.33(a), DEA is providing notice that 

on December 29, 2020, Groff NA 

Hemplex LLC, 100 Redco Avenue, Suite 

A, Red Lion, Pennsylvania 17356–1436, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substances: 

Controlled substance Drug 

code Schedule 

Marihuana Extract ........... 7350 I 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–04810 Filed 3–8–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1121–0197] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Extension 

Without Change, of a Previously 

Approved Collection; State Criminal 

Alien Assistance Program (Section 

241(i) of the Immigration and 

Nationality Act (8 U.S.C. 1231(i)) 

AGENCY: Bureau of Justice Assistance, 

Department of Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice 

(DOJ), Office of Justice Programs, 

Bureau of Justice Assistance, will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted 60 days until May 10, 

2021. 

FOR FURTHER INFORMATION CONTACT: If 

you have additional comments on the 

estimated burden to facilities covered by 

the standards to comply with the 

regulation’s reporting requirements, 

suggestions, or need additional 

information, please contact, Joseph 

Husted, telephone number (202) 906– 

0387, Policy Advisor, Bureau of Justice 

Assistance, 810 Seventh Street NW, 

Washington, DC 20531 or by email at 

SCAAP@usdoj.gov. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions that 

were used; 

—Evaluate whether and if so how the 

quality, utility, and clarity of the 

information collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including use of appropriate 

automated, electronic, mechanical, or 

other technological collection 

techniques or other forms of 


khammond on DSKJM1Z7X2PROD with NOTICES